Click here to listen.
I do the “ETF of the Week” for MarketWatch every Thursday on Chuck Jaffe’s MoneyLife Show where I highlight big movers and disappointments within the exchange traded fund market.
This week, I looked at the SPDR S&P Biotech ETF (NYSEArca: XBI). With an aging population, the shift to more specialized drug products and now the full backing of the health care reform, the biotechnology sector has been one of the best performing sectors this year.
The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.